Some studies have shown that TP53 alterations are more frequent in serous adenocarcinoma and in poorly differentiated tumours (Geisler et al, 1997; Leitao et al, 2002; Skirnisdottir et al, 2002), while others were not able to demonstrate these differences (Marks et al, 1991; Fallows et al, 2001; Leitao et al, 2002). Here, TP53 is linked to neoplasm.